查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668075

膽道癌市場 - 全球產業規模、佔有率、趨勢、機會和預測，按癌症類型、最終用戶、地區和競爭細分，2020-2030 年預測

Biliary Tract Cancers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Cancer Type, By End-User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球膽道癌市場價值為 6.4505 億美元，預計在預測期內將保持穩定成長，到 2030 年的複合年成長率為 4.75%。膽道癌（包括膽管癌和膽囊癌）為醫療保健產業帶來了獨特的挑戰和機會。本市場概覽旨在闡明全球膽道癌市場的現況。

市場概況
預測期 2026-2030
2024 年市場規模 6.4505 億美元
2030 年市場規模 8.5415 億美元
2025-2030 年複合年成長率 4.75％
成長最快的領域 肝外膽管癌 (EHC)
最大的市場 北美洲

與其他癌症相比，膽道癌相對罕見，但近年來發病率呈上升趨勢。生活方式的改變、肥胖率的上升、接觸環境毒素以及肝吸蟲感染等特定風險因素導致了該疾病發生率的上升。了解膽道癌的流行程度對於市場利害關係人評估潛在患者群體至關重要。

主要市場促進因素

膽道癌（BTC）發生率和盛行率不斷上升

主要市場挑戰

認知有限且診斷較晚

主要市場趨勢

免疫療法徹底改變治療方法

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第 5 章：膽道癌市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依癌症類型（肝內膽管癌 (ICC)、肝外膽管癌、膽囊癌）
    • 按最終使用者（醫院、專科癌症中心、門診手術中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美膽道癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲膽道癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太膽道癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲膽道癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲膽道癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球膽道癌市場：SWOT 分析

第 14 章：競爭格局

  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Bayer AG
  • AstraZeneca plc

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 17636

Global Biliary Tract Cancers Market was valued at USD 645.05 Million in 2024 and is anticipated to project Steady growth in the forecast period with a CAGR of 4.75% through 2030. The Global Biliary Tract Cancer Market is a dynamic and evolving sector within the broader field of oncology. Biliary tract cancer, which includes cancers of the bile ducts and gallbladder, poses unique challenges and opportunities for the healthcare industry. This market overview aims to shed light on the current state of the Global Biliary Tract Cancer Market.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 645.05 Million
Market Size 2030USD 854.15 Million
CAGR 2025-20304.75%
Fastest Growing SegmentExtrahepatic Cholangiocarcinoma (EHC)
Largest MarketNorth America

Biliary tract cancer, while relatively rare compared to some other cancers, has been on the rise in recent years. Factors such as changing lifestyles, increased obesity rates, exposure to environmental toxins, and specific risk factors like liver fluke infections have contributed to the increasing incidence of this disease. Understanding the prevalence of biliary tract cancer is crucial for market stakeholders to assess the potential patient population.

Key Market Drivers

Increasing Incidence and Prevalence of Biliary Tract Cancers (BTCs)

The increasing incidence and prevalence of biliary tract cancers (BTCs) are key market drivers that significantly impact the Global Biliary Tract Cancers Market. According to the Global Burden of Disease Study, the global age-standardized incidence rate (ASR) for biliary tract cancers (BTCs) is 2.5 cases per 100,000 individuals. However, incidence rates vary significantly based on tumor location (intrahepatic vs. extrahepatic cholangiocarcinoma, gallbladder cancer), geographic region, and gender, reflecting differences in genetic predisposition, environmental risk factors, and healthcare accessibility across populations. This rising trend is fueling demand for diagnostics, therapeutics, and supportive care solutions, creating lucrative opportunities for pharmaceutical companies, biotech firms, and healthcare providers. The growing number of diagnosed BTC cases worldwide is directly increasing the demand for treatment options. The Global Burden of Disease Study reported 139,500 deaths from biliary tract cancers (BTCs) in 2013, marking a 22% increase from the 115,400 deaths recorded in 1990. This rise corresponds to an increase in the age-standardized mortality rate, from 2.3 deaths per 100,000 individuals per year in 1990 to 3.4 per 100,000 per year in 2013, highlighting a growing disease burden and the need for enhanced diagnostic and treatment strategies. With biliary tract cancers being aggressive and often diagnosed at advanced stages, the need for effective chemotherapy, targeted therapies, and immunotherapies is rising. Increased drug sales for existing therapies. Greater investment in clinical research and drug development. Expansion of treatment facilities and specialized cancer centers.

Key Market Challenges

Limited Awareness and Late-Stage Diagnoses

One of the foremost challenges facing the Global Biliary Tract Cancer Market is the limited awareness among the general population and healthcare providers regarding this particular cancer type. Biliary tract cancer often presents with non-specific symptoms, leading to delayed diagnoses. Many individuals and even some healthcare professionals may not be adequately familiar with these symptoms, which can include jaundice, abdominal pain, and unexplained weight loss.

The lack of early detection can result in patients being diagnosed at advanced stages of the disease, when treatment options are more limited and prognosis is less favorable. This not only hampers patient outcomes but also reduces the potential market size for early-stage therapies and interventions.

Key Market Trends

Immunotherapy Revolutionizing Treatment Approaches

One of the most significant trends shaping the Global Biliary Tract Cancer Market is the emergence of immunotherapy as a promising treatment option. Immunotherapeutic agents, such as immune checkpoint inhibitors, have shown remarkable efficacy in various cancer types, including biliary tract cancer. These agents work by stimulating the body's immune system to recognize and target cancer cells, offering new hope for patients.

The trend towards immunotherapy is driven by a growing body of clinical evidence supporting its effectiveness. Clinical trials have demonstrated prolonged survival rates and improved outcomes for patients with advanced biliary tract cancer. This has led to increased research and investment in immunotherapeutic approaches, with pharmaceutical companies developing novel drugs and therapies targeting this specific cancer type.

Key Market Players

  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Bayer AG
  • AstraZeneca plc

Report Scope:

In this report, the Global Biliary Tract Cancers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biliary Tract Cancers Market, By Cancer Type:

  • Intrahepatic Cholangiocarcinoma (ICC)
  • Extrahepatic Cholangiocarcinoma
  • Gallbladder Cancer

Biliary Tract Cancers Market, By End-User:

  • Hospitals
  • Specialty Cancer Centres
  • Ambulatory Surgical Centres
  • Others

Biliary Tract Cancers Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biliary Tract Cancers Market.

Available Customizations:

Global Biliary Tract Cancers market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Biliary Tract Cancers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Type (Intrahepatic Cholangiocarcinoma (ICC), Extrahepatic Cholangiocarcinoma, Gallbladder Cancer)
    • 5.2.2. By End-User (Hospitals, Specialty Cancer Centres, Ambulatory Surgical Centres, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Biliary Tract Cancers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biliary Tract Cancers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Biliary Tract Cancers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Biliary Tract Cancers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Type
        • 6.3.3.2.2. By End User

7. Europe Biliary Tract Cancers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biliary Tract Cancers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Biliary Tract Cancers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Biliary Tract Cancers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Biliary Tract Cancers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Biliary Tract Cancers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Biliary Tract Cancers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biliary Tract Cancers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Biliary Tract Cancers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Biliary Tract Cancers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Biliary Tract Cancers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Biliary Tract Cancers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By End User

9. South America Biliary Tract Cancers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biliary Tract Cancers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Biliary Tract Cancers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Biliary Tract Cancers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Biliary Tract Cancers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biliary Tract Cancers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Biliary Tract Cancers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Biliary Tract Cancers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Biliary Tract Cancers Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Bristol-Myers Squibb
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Eli Lilly and Company
  • 14.3. F. Hoffmann-La Roche Ltd.
  • 14.4. Johnson & Johnson Services, Inc
  • 14.5. Merck & Co., Inc.
  • 14.6. Novartis AG
  • 14.7. Pfizer Inc.
  • 14.8. Sanofi SA
  • 14.9. Bayer AG
  • 14.10.AstraZeneca plc

15. Strategic Recommendations

16. About Us & Disclaimer